Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

• Status: Completed
• Trial end date: 2009-05-01

Summary

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide 25 mg (Madopar HBS).

• Phase: Phase 1

Details

• Lead Sponsor: Bial - Portela C S.A.
• Treatments: Benserazide; Benserazide, levodopa drug combination; Levodopa; Opicapone